Joori Kim1, Kabsoo Shin1, Sung Hak Lee2, In-Ho Kim1. 1. Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea. 2. Department of Clinical Pathology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Abstract
BACKGROUND: Slug is an activating transcription factor involved in epithelial-mesenchymal transition, and CD133 is a cancer stem cell marker found in various cancers, including gastric cancer (GC). We investigated the relationship between Slug and CD133 and the occurrence of peritoneal carcinomatosis and survival in patients with GC. METHODS: This retrospective study included 196 patients with stage 2 or 3 GC who underwent curative surgery with D2 lymph node dissection and adjuvant chemotherapy between 2001 and 2009. We analyzed the expression of Slug, CD133, ABCG2, E-cadherin, vimentin, NEDD9, and SMAD4 in surgical tissue specimens using immunohistochemical analysis to determine their prognostic value. RESULTS: Among the 196 patients, expression of Slug was elevated in 157 tumors (81%) while the expression of CD133 was high in 153 tumors (81%). The expression of Slug and CD133 in combination significantly predicted peritoneal relapse (P=0.002). High Slug and high CD133 expression were significantly associated with poor peritoneal relapse-free survival [hazard ratio (HR), 7.239; P=0.007] and overall survival (HR, 1.682; P=0.027) in multivariate Cox analysis. CONCLUSIONS: Our study shows that a high Slug and high CD133 expression status is predictive of peritoneal recurrence in high-risk resected GC patients. They are also a poor prognostic factor for peritoneal relapse-free survival and overall survival. 2021 Journal of Gastrointestinal Oncology. All rights reserved.
BACKGROUND: Slug is an activating transcription factor involved in epithelial-mesenchymal transition, and CD133 is a cancer stem cell marker found in various cancers, including gastric cancer (GC). We investigated the relationship between Slug and CD133 and the occurrence of peritoneal carcinomatosis and survival in patients with GC. METHODS: This retrospective study included 196 patients with stage 2 or 3 GC who underwent curative surgery with D2 lymph node dissection and adjuvant chemotherapy between 2001 and 2009. We analyzed the expression of Slug, CD133, ABCG2, E-cadherin, vimentin, NEDD9, and SMAD4 in surgical tissue specimens using immunohistochemical analysis to determine their prognostic value. RESULTS: Among the 196 patients, expression of Slug was elevated in 157 tumors (81%) while the expression of CD133 was high in 153 tumors (81%). The expression of Slug and CD133 in combination significantly predicted peritoneal relapse (P=0.002). High Slug and high CD133 expression were significantly associated with poor peritoneal relapse-free survival [hazard ratio (HR), 7.239; P=0.007] and overall survival (HR, 1.682; P=0.027) in multivariate Cox analysis. CONCLUSIONS: Our study shows that a high Slug and high CD133 expression status is predictive of peritoneal recurrence in high-risk resected GC patients. They are also a poor prognostic factor for peritoneal relapse-free survival and overall survival. 2021 Journal of Gastrointestinal Oncology. All rights reserved.
Authors: Christina Scheel; Elinor Ng Eaton; Sophia Hsin-Jung Li; Christine L Chaffer; Ferenc Reinhardt; Kong-Jie Kah; George Bell; Wenjun Guo; Jeffrey Rubin; Andrea L Richardson; Robert A Weinberg Journal: Cell Date: 2011-06-10 Impact factor: 41.582
Authors: Christophe Côme; Fabrice Magnino; Frédéric Bibeau; Pascal De Santa Barbara; Karl Friedrich Becker; Charles Theillet; Pierre Savagner Journal: Clin Cancer Res Date: 2006-09-15 Impact factor: 12.531
Authors: Michael D'Angelica; Mithat Gonen; Murray F Brennan; Alan D Turnbull; Manjit Bains; Martin S Karpeh Journal: Ann Surg Date: 2004-11 Impact factor: 12.969